SIM0916

Simcere Pharmaceutical Co., Ltd · Phase 3 active Small molecule

SIM0916 is a small molecule inhibitor that targets a specific molecular pathway involved in disease pathogenesis, though the exact mechanism requires further clarification.

At a glance

Generic name	SIM0916
Sponsor	Simcere Pharmaceutical Co., Ltd
Modality	Small molecule
Phase	Phase 3

Mechanism of action

SIM0916 is an investigational drug in Phase 3 development by Simcere Pharmaceutical Co., Ltd. Limited public information is available regarding its precise molecular mechanism and target. Additional clinical trial data would be needed to fully characterize its mechanism of action.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Phase III Clinical Trial on the Efficacy and Safety of Deuremidevir Hydrobromide Dry Suspension for the Treatment of RSV Infection in Infants and Young Children (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

SIM0916 CI brief — competitive landscape report
SIM0916 updates RSS · CI watch RSS
Simcere Pharmaceutical Co., Ltd portfolio CI